Research conducted at Yale University School of Medicine has shown that Zebinix, a once-daily anti-epileptic drug, can help to decrease seizure frequency over the long term.

Results from a one-year extension of an Eslicarbazepine Acetate Phase III study showed that an add-on treatment with once-daily anti-epileptic Zebinix (eslicarbazepine acetate; ESL) showed a sustained decrease in seizure frequency over the long term.

Patients not on existing anti-epileptic drugs who were given Zebinix as an add-on treatment experienced a mean reduction in seizure frequency of more than 61%.

Yale University School of Medicine research scientist and president of The Epilepsy Therapy Project Joyce Cramer said that the data continue to demonstrate the efficacy and safety of Zebinix in the treatment of partial onset seizures.

“The availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control,” Cramer said.

The data was pooled from over 1,000 patients enrolled in the three pivotal Phase III studies.